Electroconvulsive therapy (ECT) remains a contentious treatment in psychiatry, sparking ongoing debate over its benefits and risks, particularly concerning its effects on memory and its role in managing severe mental illness. The treatment is primarily used for conditions such as bipolar disorder and treatment-resistant depression, with proponents highlighting its efficacy while critics point to potential long-term cognitive side effects.
Dr. Rebecca Lawrence, a consultant psychiatrist and author who has undergone multiple courses of ECT, describes the treatment as both effective and challenging. She acknowledges that while ECT brought relief from severe symptoms of bipolar disorder, it also resulted in enduring difficulties with autobiographical memory. Despite these cognitive side effects, she emphasizes that the therapy may be preferable to the potentially fatal course of untreated bipolar disorder. Lawrence notes that ECT is neither a miraculous cure nor an inhumane procedure but a clinical intervention used in response to severe psychiatric conditions. She advocates for greater recognition of the long-term memory impairments associated with ECT and calls for improved support systems following treatment.
Standards for ECT practice are maintained in Scotland by the Scottish ECT Accreditation Network (SEAN), coordinated by Public Health Scotland, while the Royal College of Psychiatrists’ ECT Accreditation Service (ECTAS) performs a similar role in other parts of the UK. However, access to ECT—and mental health treatments in general—remains uneven across regions, a problem partly attributed to varied resource allocation among healthcare trusts. This "postcode prescribing" aspect can lead to prolonged waiting times and limited availability of therapies, including psychological approaches, medication, and ECT itself.
In response to criticism of ECT, Professor George Kirov of the University of Edinburgh stressed the importance of balanced and evidence-based discussion. He pointed out that while memory problems are acknowledged among clinicians and outlined in patient information, severe cognitive impairments are rare. According to Kirov’s clinical experience spanning 25 years and over 450 patients, he has not encountered cases of patients losing fundamental abilities such as reading or recognizing their children due to ECT. Instead, some patients even regained such faculties after treatment, which had been compromised by severe mental illness.
National data from the UK indicate that about two-thirds of ECT recipients experience marked clinical improvement, often restoring significant functioning in individuals with the most severe and treatment-resistant conditions. Kirov also addresses common misconceptions, such as the absence of placebo-controlled trials, explaining that while early trials established ECT efficacy, subsequent research has compared it favorably against antidepressants and alternative brain stimulation methods. Additionally, the higher proportion of women receiving ECT aligns with the higher prevalence of depression among women globally, rather than indicating misdiagnosis or bias.
Although regional disparities in ECT provision exist, data from England’s 71 clinics show that all patients can be referred for treatment, with variation primarily linked to differing local service capacity rather than outright denial of access.
Critics of ECT, and some media portrayals, often amplify concerns about the treatment, which Kirov argues contributes to stigma and may discourage patients from benefiting from a well-supported medical option. Both Lawrence and Kirov underscore the complexity of ECT as a treatment, suggesting that understanding its role requires careful consideration of individual patient experiences alongside robust clinical evidence.